Bio-Rad Laboratories Inc (BIO)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.85B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bio-Rad Laboratories Inc (BIO) Financials: Revenue, Profit and Cash Flow
Bio-Rad Laboratories reported revenue of $2.58B for the fiscal year ended Dec 31, 2025, up 0.7% from the year before. That year, net income was $759.90M with a net margin of 29.4%, operating cash flow was $532.20M and free cash flow was $374.60M. The quarter ended Sep 30, 2026 had revenue of $656.40M and net income of $458.60M.
Revenue and Margins
The operating margin was 1.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.07B, a compound annual rate of 2.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.58B | +0.7% | 51.9% | 1.8% | 29.4% |
| Dec 2024 | $2.57B | -3.9% | 53.7% | 10.5% | -71.9% |
| Dec 2023 | $2.67B | -4.7% | 53.4% | 12.6% | -23.9% |
| Dec 2022 | $2.80B | -4.1% | 55.9% | 17.2% | -129.5% |
| Dec 2021 | $2.92B | +14.8% | 56.1% | 17.1% | 145.6% |
| Dec 2020 | $2.55B | +10.1% | 56.5% | 16.6% | 149.8% |
| Dec 2019 | $2.31B | +1.0% | 54.4% | 9.9% | 76.1% |
| Dec 2018 | $2.29B | +6.0% | 53.4% | -4.5% | 16.0% |
| Dec 2017 | $2.16B | +4.4% | 55.0% | 5.5% | 5.7% |
| Dec 2016 | $2.07B | N/A | 55.0% | 2.7% | 1.3% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B | $1.05B | $1.07B | $972.45M | $929.74M |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B |
| Research and development | $275.60M | $295.90M | $247.40M | $256.90M | $260.64M | $217.76M | $202.71M | $199.20M | $250.16M | $205.71M |
| Operating income | $47.20M | $269.00M | $337.80M | $482.60M | $500.34M | $421.33M | $229.66M | -$103.34M | $119.25M | $55.72M |
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | $4.25B | $3.81B | $1.76B | $365.61M | $122.25M | $26.00M |
| EBITDA | $144.10M | $363.20M | $451.60M | $527.50M | $524.36M | $444.04M | $253.51M | $536.62M | $120.82M | $64.94M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $656.40M | $651.00M | $592.10M | $693.20M | $653.00M | $651.60M | $585.40M | $667.50M | $649.70M | $638.50M | $610.80M | $681.12M |
| Gross profit | $328.60M | $345.80M | $309.40M | $345.20M | $343.40M | $345.30M | $306.00M | $342.00M | $355.90M | $355.10M | $325.90M | $366.32M |
| Operating income | -$49.70M | $72.60M | $34.10M | -$118.90M | $65.30M | $77.10M | $23.70M | $58.40M | $64.50M | $101.50M | $44.60M | $95.32M |
| Net income | $458.60M | $371.40M | -$527.10M | $720.00M | -$341.90M | $317.80M | $64.00M | -$715.80M | $653.20M | -$2.17B | $383.90M | $349.73M |
Balance Sheet
As of Dec 2025, total debt of $1.20B exceeded cash and equivalents by $673.20M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B | $12.97B | $8.01B | $5.61B | $4.27B | $3.85B |
| Current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B | $2.14B | $2.18B | $2.02B | $1.98B | $1.84B |
| Cash and equivalents | $529.80M | $488.10M | $403.80M | $434.21M | $470.78M | $662.21M | $660.67M | $431.53M | $383.82M | $456.26M |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B | $2.25B | $1.59B | $1.34B | $1.27B |
| Short-term debt | $1.30M | $1.20M | $500.00K | $465.00K | $489.00K | $1.80M | $426.17M | $493.00K | $420.00K | $334.00K |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | $10.51M | $12.26M | $13.58M | $438.94M | $434.58M | $434.19M |
| Shareholder equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B | $9.88B | $5.76B | $4.02B | $2.93B | $2.58B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.78B | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B | $10.60B | $9.69B | $12.61B | $12.30B |
| Total liabilities | $3.18B | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B | $3.12B | $2.91B | $3.56B | $3.56B |
| Cash and equivalents | $465.30M | $517.00M | $507.20M | $531.80M | $395.80M | $369.30M | $521.40M | $488.10M | $410.38M | $406.91M | $433.28M | $403.81M |
| Shareholder equity | $7.60B | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B | $7.49B | $6.78B | $9.05B | $8.74B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 70.4% of operating cash flow. Share repurchases came to 78.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $532.20M | $455.20M | $374.90M | $17.60M | $669.46M | $584.97M | $285.00K | $285.49M | -$17.72M | $216.07M |
| Capital expenditures | $157.60M | $165.60M | $156.70M | $112.80M | $133.75M | $108.56M | $98.53M | $129.82M | $115.13M | $141.44M |
| Free cash flow | $374.60M | $289.60M | $218.20M | -$95.20M | $535.72M | $476.41M | -$98.25M | $155.67M | -$132.85M | $74.63M |
| Dividends paid | N/A | N/A | $100.10B | $68.18B | $35.28B | $20.20M | $3.83B | N/A | $4.37M | N/A |
| Share repurchases | $295.50M | $203.60M | $428.70M | $215.70M | $50.00M | $100.00M | $28.00M | $48.91M | $2.92M | $0 |
| Investing cash flow | -$189.70M | -$160.20M | $20.20M | -$1.21B | -$797.38M | -$69.89M | -$208.89M | -$186.98M | -$175.57M | -$213.88M |
| Financing cash flow | -$283.20M | -$218.80M | -$425.60M | $973.60M | -$55.43M | -$523.04M | -$22.76M | -$48.68M | $341.00K | $9.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.40M | -$131.40M | $108.10M | $577.70M | $120.90M | $268.60M | -$22.20M | $500.80M | -$22.30M | -$900.00K | -$22.40M | $374.90M |
| Capital expenditures | $31.20M | $32.00M | $30.00M | $45.80M | $31.70M | $45.70M | $34.40M | $42.90M | $40.20M | $42.30M | $40.20M | $42.27M |
| Free cash flow | -$53.60M | -$163.40M | $78.10M | $531.90M | $89.20M | $222.90M | -$56.60M | $457.90M | -$62.50M | -$43.20M | -$62.60M | $332.63M |
Frequently Asked Questions About BIO
What is Bio-Rad Laboratories' annual revenue?
Bio-Rad Laboratories reported revenue of $2.58B for the fiscal year ended Dec 31, 2025.
How fast is Bio-Rad Laboratories' revenue growing?
Revenue was up 0.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.7%.
Is Bio-Rad Laboratories profitable?
Yes. Bio-Rad Laboratories reported net income of $759.90M for the fiscal year ended Dec 31, 2025, with a net margin of 29.4%.
How much free cash flow does BIO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $532.20M minus capital expenditures of $157.60M produced free cash flow of $374.60M.
How much debt does Bio-Rad Laboratories have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.20B, short-term debt of $1.30M and cash and equivalents of $529.80M.
BIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors